The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).
 
Jenny HJ Lee
Travel, Accommodations, Expenses - AstraZeneca; Bio-Rad; Bristol-Myers Squibb (Mexico)
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Justin Iver Odegaard
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Martina Lefterova
Employment - Guardant Health
 
Richard A. Scolyer
Consulting or Advisory Role - Merck Sharp & Dohme; Myriad Pharmaceuticals; NeraCare GmbH; Novartis
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Helen Rizos
No Relationships to Disclose